First Tracks Biotherapeutics Completes Spin-Off & $145M Private Placement

First Tracks Biotherapeutics, Inc. completed its spin-off from AnaptysBio, Inc. on April 20, 2026. As part of the spin-off, AnaptysBio shareholders received one share of First Tracks common stock for every one share of AnaptysBio common stock held. Concurrently, First Tracks completed a private placement, issuing 5,791,478 shares and a selling stockholder selling 4,705,575 shares, both at a purchase price of $13.81 per share, totaling approximately $145 million. This establishes First Tracks as an independent public entity with new capital.